EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long‐term real‐world effectiveness of deucravacitinib in psoriasis: A 52‐week prospective study stratified by prior apremilast or biologic therapy

Teppei Hagino iD, Hidehisa Saeki iD, Eita Fujimoto iD, Naoko Kanda iD

The Journal of Dermatology · 2025-04 · 52 (4) · 634-641

DOI: 10.1111/1346-8138.17665 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, online erschienen am 07.02.2025. Verfasst von Teppei Hagino und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan. Hauptthemen laut MEDLINE: Psoriasis, Thalidomide, Protein Kinase Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Real‐world evidence on the long‐term effectiveness of deucravacitinib, a selective tyrosine kinase 2 inhibitor for psoriasis, remains limited, particularly in patients with different histories of systemic treatments. We evaluated the 52‐week effectiveness of deucravacitinib in patients with psoriasis, stratified by a history of apremilast or biologic usage. This prospective, single‐center study included 110 patients with moderate‐to‐severe psoriasis who received daily deucravacitinib (6 mg). Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores during the treatment were analyzed in subgroups stratified by a history of apremilast or biologic usage. Deucravacitinib decreased PASI and DLQI scores for 52 weeks in psoriasis patients, both with and without prior apremilast or biologic usage. The percent reductions from baseline PASI or DLQI at week 52 were similar in apremilast‐experienced patients (92% or 77.9%) and apremilast‐naive patients (88.3% or 81.6%), respectively. The achievement rates of PASI 100 or absolute PASI ≤1 at week 52 in apremilast‐experienced patients (30.8% or 61.5%) were slightly higher than those in apremilast‐naive patients (20.5% or 46.2%). The percent reductions from baseline PASI or DLQI at week 52 in biologic‐naive patients (91.6 or 82.8%) were slightly higher than those in biologic‐experienced patients (57.6% or 63.6%), respectively. The achievement rates of PASI 75, 100 or absolute PASI ≤1 at week 52 in biologic‐naive patients (84.4%, 24.4%, or 53.3%) were slightly higher than those in biologic‐experienced patients (57.1%, 14.3%, or 28.6%), respectively. Deucravacitinib generated sustained 52‐week effectiveness in diverse patient subgroups, supporting its role as a universal treatment for psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisThalidomideProtein Kinase InhibitorsHumansMaleFemaleMiddle AgedProspective StudiesTreatment OutcomeAdultSeverity of Illness IndexQuality of LifeAged

Stichwörter der Autor:innen

apremilastbiologicdeucravacitiniblong‐termpsoriasistyrosine kinase 2

Substanzen

apremilastThalidomideProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
  • Department of Dermatology, Nippon Medical School, Tokyo, Japan.
  • Department of Dermatology, Fujimoto Dermatology Clinic, Funabashi, Japan.

ORCID-Profile: Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Zitieren

APA

Hagino, T., Saeki, H., Fujimoto, E., & Kanda, N. (2025). Long‐term real‐world effectiveness of deucravacitinib in psoriasis: A 52‐week prospective study stratified by prior apremilast or biologic therapy. The Journal of Dermatology, 52(4), 634-641. https://doi.org/10.1111/1346-8138.17665

Vancouver

Hagino T, Saeki H, Fujimoto E, Kanda N. Long‐term real‐world effectiveness of deucravacitinib in psoriasis: A 52‐week prospective study stratified by prior apremilast or biologic therapy. The Journal of Dermatology. 2025;52(4):634-641. doi:10.1111/1346-8138.17665

BibTeX
@article{Hagino2025,
  author = {Hagino, Teppei and Saeki, Hidehisa and Fujimoto, Eita and Kanda, Naoko},
  title = {Long‐term real‐world effectiveness of deucravacitinib in psoriasis: A 52‐week prospective study stratified by prior apremilast or biologic therapy},
  journal = {The Journal of Dermatology},
  year = {2025},
  volume = {52},
  number = {4},
  pages = {634--641},
  doi = {10.1111/1346-8138.17665}
}
Kostenlos starten →